Discover investment opportunities in Stocks Under 5 Bucks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks Under 5 Bucks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks Under 5 Bucks using our Smart AI Filter.
8 stocks found for "Stocks Under 5 Bucks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.79 Risk measure | ±66.5% Price volatility | 4.1 Valuation | 0.00% Annual yield | |||
0.65 Risk measure | ±52.7% Price volatility | 7.9 Valuation | 4.57% Annual yield | |||
1.79 Risk measure | ±95.5% Price volatility | -2.0 Valuation | 0.00% Annual yield | |||
1.95 Risk measure | ±100.0% Price volatility | -0.9 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±71.0% Price volatility | -1.1 Valuation | 0.00% Annual yield | |||
0.76 Risk measure | ±41.4% Price volatility | 25.6 Valuation | 0.00% Annual yield | |||
0.61 Risk measure | ±38.9% Price volatility | 6.7 Valuation | 5.08% Annual yield | |||
1.06 Risk measure | ±43.4% Price volatility | 5.8 Valuation | 3.42% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: Why might ATAI Life Sciences be considered a potential growth stock?
A: ATAI Life Sciences focuses on mental health innovation through a biotech approach, potentially benefiting from increased awareness and investment in mental health solutions. However, as with most biotech stocks, revenue volatility and dependence on clinical trial outcomes can impact growth stability.
Q: What factors could make Western Copper and Gold (WRN) attractive in a global commodities market?
A: WRN is involved in copper and gold mining, essential for electronics and renewable energy. Rising demand for these commodities can enhance WRN's appeal, but investors should consider commodity price volatility and geopolitical risks affecting mining operations.
Q: What risks should investors consider with Osteopore Limited (OSTX)?
A: Osteopore Limited, focusing on 3D printed bioresorbable implants, relies heavily on innovative technology and regulatory approvals. Given this, investors should monitor the competitive landscape and potential for regulatory changes affecting market access.
Q: How does MannKind Corporation (MNKD) stand out in the biotech industry?
A: MannKind Corporation is known for its inhalable insulin product, Afrezza, catering to diabetes care. While innovative, MNKD faces challenges from established competitors and patent expirations, factors to consider when evaluating its long-term position.
Q: Could an ETF like Horizons Uranium ETF (HURA) offer benefits in a diversified portfolio?
A: Horizons Uranium ETF provides exposure to uranium markets, which may appeal to those banking on nuclear energy's role in energy transition. Volatility in energy prices and shifts in nuclear policy are critical factors affecting HURA's performance.
Q: What potential advantages does Reviva Pharmaceuticals (RVPH) have in the small-cap pharma sector?
A: Reviva Pharmaceuticals specializes in oral drug candidates addressing unmet medical needs. Its focus on neuropsychiatric disorders could be advantageous amidst rising mental health awareness. However, its financial stability depends heavily on successful clinical trials.
The consensus price target hints at a 39.6% upside potential for FuelCell Energy (FCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read more